Clinical Trial

FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)

Study acronym: MIM
Recruiting
View on ClinicalTrials.gov →
Summary
Hybrid positron emission tomography/computed tomography (PET/CT) has now become available to detect tumors in patients with multiple myeloma. The radioactive glucose 18F-fluorodeoxyglucose (FDG) is the most widely used tracer but findings suggest that PET/CT reveal more lesions when using FCH. In this study, FDG is compared with a more recent metabolic tracer, 18F-fluorocholine (FCH), for the detection of multiple myeloma lesions at time of initial extension assessment. The principal objective of this sudy is to compare the number of suspected hypermetabolic foci of myeloma detected by 18F-fluorocholine PET and by 18F-fluorodeoxyglucose PET during the initial extension assessment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-04-15; most recent amendment 2023-10-16.
Status change: Not Yet Recruiting → Recruiting 2021-05-21
Trial Details
NCT Number NCT04349358
Lead Sponsor Centre Georges Francois Leclerc
Conditions Multiple Myeloma
Enrollment 38 participants
Start Date 2020-12-15
Primary Completion 2022-12-15 (estimated)
Study Completion 2030-12-15 (estimated)
Updated on ClinicalTrials.gov 2023-10-17